J. Lippitt

发表

Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL‐Induced Apoptosis

F. Hamdy, I. Holen, N. Cross, 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

I. Holen, P. Croucher, T. Skerry, 2001, Blood.

Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer

F. Hamdy, A. Wetterwald, M. Cecchini, 2010, The Prostate.

Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin.

G. Morgan, S. Rollinson, P. Croucher, 2003, Immunity.

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

P. Croucher, M. Rogers, D. Hughes, 2000 .

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma

P. Croucher, M. Rogers, D. Hughes, 2000, British journal of haematology.

Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival?

S. Cross, I. Holen, S. Balasubramanian, 2005, Breast Cancer Research and Treatment.

High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer.

F. Hamdy, M. Cecchini, G. Thalmann, 2010, Cancer research.

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.

P. Croucher, G. Russell, K. Vanderkerken, 2000 .

Eight‐plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study

S. Cross, F. Hamdy, P. Wright, 2010, The Prostate.

Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables

S. Cross, I. Holen, M. Reed, 2006, Journal of Clinical Pathology.

Zoledronic Acid Treatment of 5T2MM‐Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival

E. van Marck, P. Croucher, K. Vanderkerken, 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

multiple myeloma Osteoprotegerin inhibits the development of osteolytic bone disease in

I. Holen, T. Skerry, G. Russell, 2013 .

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma

P. Croucher, E. Marck, K. Vanderkerken, 2002 .

Osteoprotegerin (OPG)—a potential new role in the regulation of endothelialcell phenotype and tumour angiogenesis?

I. Holen, M. Reed, S. Balasubramanian, 2006, International journal of cancer.

Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer

F. Hamdy, A. Wetterwald, M. Cecchini, 2010, The Prostate.